Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 adenovirus vector vaccine (Rong'an Biological)
- Development stage
- Preclinical
- Lead developer
- Rong'an Biological
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The COVID-19 adenovirus vector vaccine is a preclinical-stage vaccine candidate developed by Rong'an Biological, a subsidiary of AIM Vaccine. It utilizes an adenovirus vector platform to deliver the genetic sequence of the SARS-CoV-2 spike protein into the recipient's cells. Once inside, the cells produce the spike protein, which then triggers the immune system to generate antibodies and T-cell responses. This specific candidate is designed with a broad-spectrum intent, aiming to provide protection against a wide range of SARS-CoV-2 variants. It is part of AIM Vaccine's diversified COVID-19 vaccine pipeline, which also includes mRNA and inactivated vaccine technologies.
- Other names
- Broad-spectrum adenovirus-vectored COVID-19 vaccineRong'an COVID-19 adenovirus vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on COVID-19 adenovirus vector vaccine (Rong'an Biological).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 adenovirus vector vaccine (Rong'an Biological).